Free Trial

ProShares Ultra Nasdaq Biotechnology Rating

ProShares Ultra Nasdaq Biotechnology logo
$82.85 +0.31 (+0.38%)
Closing price 03:59 PM Eastern
Extended Trading
$82.84 -0.01 (-0.01%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2026)

MarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.

BIB Aggregate Rating

Moderate Buy
2.72

Holdings in BIB have an aggregate rating of Moderate Buy based on 400 analyst ratings issued in the past year covering 19 companies (35.8% of the portfolio).

BIB Aggregate Price Target

$82.85
High Prediction$82.85
Average Prediction$82.85
Low Prediction$82.85

Holdings in BIB have an aggregate price target of $82.85 and a range of $82.85 to $82.85 covering 19 companies (35.8% of the portfolio).

BIB Consensus Ratings of Holdings

Strong Buy
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
Moderate Buy
11 Moderate Buy rating(s)
Hold
4 Hold rating(s)
Reduce
1 Reduce rating(s)
Sell
0 Sell rating(s)
Strong Sell
0 Strong Sell rating(s)

Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology

 
 
Strong Sell
Sell
Reduce
Hold
Moderate Buy
Buy
Strong Buy

Ratings for the Top 19 BIB Holdings

Weight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)View
Ratings
4.86%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$133.48
+0.6%
4.8337 of 5 stars
2.86$157.35 17.9%28
4.72%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$424.36
-1.3%
4.6035 of 5 stars
2.83$554.83 30.7%29
4.55%
Amgen Inc. stock logo
AMGN
Amgen
$329.59
+1.8%
4.4701 of 5 stars
2.42$357.12 8.4%31
3.90%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$702.45
-1.0%
4.2943 of 5 stars
2.77$826.59 17.7%26
2.09%
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$301.11
+1.1%
4.3421 of 5 stars
2.81$471.96 56.7%26
1.60%
Insmed, Inc. stock logo
INSM
Insmed
$139.44
-0.4%
3.3716 of 5 stars
3.00$213.23 52.9%25
1.55%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$147.21
-0.5%
2.8 of 5 stars
3.10$78.94 -46.4%21
1.46%
Biogen Inc. stock logo
BIIB
Biogen
$189.13
+1.0%
4.0892 of 5 stars
2.50$214.23 13.3%28
1.35%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$572.20
-1.6%
3.5587 of 5 stars
2.77$601.50 5.1%13
1.22%
argenex SE stock logo
ARGX
argenex
$794.70
-2.0%
3.908 of 5 stars
2.92$1,016.22 27.9%24
1.14%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$50.44
+0.5%
3.6244 of 5 stars
3.00$50.33 -0.2%6
1.13%
Illumina, Inc. stock logo
ILMN
Illumina
$139.07
-0.2%
3.065 of 5 stars
2.22$131.06 -5.8%18
1.08%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$28.32
-0.1%
2.8134 of 5 stars
2.75$30.55 7.9%12
1.02%
Incyte Corporation stock logo
INCY
Incyte
$97.47
+0.3%
4.0758 of 5 stars
2.43$104.26 7.0%21
0.99%
Moderna, Inc. stock logo
MRNA
Moderna
$46.71
-1.2%
1.138 of 5 stars
1.84$35.73 -23.5%19
0.93%
Viatris Inc. stock logo
VTRS
Viatris
$15.53
+2.2%
1.4407 of 5 stars
2.43$14.67 -5.6%7
0.75%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$225.28
-1.5%
4.0832 of 5 stars
2.95$291.56 29.4%19
0.71%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$68.78
-0.3%
3.186 of 5 stars
2.92$87.71 27.5%25
0.71%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$135.06
+0.7%
3.81 of 5 stars
2.82$180.45 33.6%22

This page (NASDAQ:BIB) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners